Browse diseases

…d in the clinic to markedly enhance adoptive T cell therapy for solid tumors.Acknowledgments C.H.P., I.S., Y.L., M.N.P., and J.D.P. are empl…

… therapies have demonstrated clinical success across a range of hematological malignancies. However, ACT’s broader application is limited by the low frequ…

…ell therapy remains less effective against solid tumors such as neuroblastoma (NB) than hematological malignancies. Key obstacles for CAR T c…

…ntitumor activity. While TCEs are effective in the treatment of hematological malignancies, achieving clinical antitumor activity in solid tumors has been…

…nd T cell engagers (TCEs) have demonstrated clinical success in hematological malignancies, however, many compelling TCE targets have remained out of reac…

…c potential of adoptive NK cell transfer remains constrained in solid tumors due to insufficient tumor infiltration efficiency. Developing a…

…y in high-risk patients.Methods A 61-year-old male patient with chronic myelomonocytic leukemia, thrombocytopenia and osteomyelitis was referred to our institu…

…rategy for overcoming the limitations of CAR T cell therapy for solid tumors. This approach enhances immune cell infiltration and activation…

…ssive tumor microenvironment (TME). To enhance efficacy against solid tumors, stimulatory cytokines have been incorporated into CAR-NK cell …